CRBN and plasma cell myeloma: After 2–6 months of Len treatment, drug resistance frequently develops as a result of down-regulation of CRBN mRNA and protein levels (Lopez-Girona et al., 2012; Gandhi et al., 2014), which also indicates that CRBN protein levels regulate the sensitivity of myeloma cells to IMiDs.